These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11479459)

  • 1. End points for cardiovascular drug trials in pediatric patients.
    Sinaiko AR; Lauer RM; Sanders SP
    Am Heart J; 2001 Aug; 142(2):229-32. PubMed ID: 11479459
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric issues and diseases.
    Lauer RM; Sanders SP
    Am Heart J; 2001 Aug; 142(2):224-8. PubMed ID: 11479458
    [No Abstract]   [Full Text] [Related]  

  • 3. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
    Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
    J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease drug discovery.
    Persidis A
    Nat Biotechnol; 1999 Sep; 17(9):930-1. PubMed ID: 10471943
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus?
    Halimi JM; Sautenet B; Gatault P; Roland M; Giraudeau B
    Fundam Clin Pharmacol; 2012 Dec; 26(6):771-82. PubMed ID: 21851387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing the morbidity benefit of a novel treatment with the potential for harm.
    Owen A
    QJM; 2006 Mar; 99(3):177-9. PubMed ID: 16490759
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes drugs pass cardiovascular risk check.
    Opar A
    Nat Rev Drug Discov; 2009 May; 8(5):343-4. PubMed ID: 19404302
    [No Abstract]   [Full Text] [Related]  

  • 9. Keeping apples and oranges separate: reassessing clinical trials that use composite end points as their primary outcome.
    Chan PS; Nallamothu BK; Hayward RA
    J Am Coll Cardiol; 2006 Aug; 48(4):850; author reply 851-2. PubMed ID: 16904570
    [No Abstract]   [Full Text] [Related]  

  • 10. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxoplasma vaccines: appropriate end points and sample size in future human clinical trials.
    Silveira C; Gargano N; Kijlstra A; Petersen E
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):905-8. PubMed ID: 19803697
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.
    Kohro T; Yamazaki T
    Hypertens Res; 2009 Feb; 32(2):109-14. PubMed ID: 19262468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 15. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study.
    Poole-Wilson PA; Lubsen J
    Lancet; 2002 Jun; 359(9324):2199; author reply 2203-4. PubMed ID: 12091001
    [No Abstract]   [Full Text] [Related]  

  • 16. End points in advanced colon cancer clinical trials: a review and proposal.
    Allegra C; Blanke C; Buyse M; Goldberg R; Grothey A; Meropol NJ; Saltz L; Venook A; Yothers G; Sargent D
    J Clin Oncol; 2007 Aug; 25(24):3572-5. PubMed ID: 17704403
    [No Abstract]   [Full Text] [Related]  

  • 17. Measurement of end points in heart failure trials: jousting at windmills?
    Hauptman PJ
    Mt Sinai J Med; 2004 Oct; 71(5):298-304. PubMed ID: 15543430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Attitude of patient associations to clinical trials of new drugs].
    Tybkjaer HW; Witte L; Johannessen MB
    Ugeskr Laeger; 2003 Apr; 165(16):1688-90. PubMed ID: 12756833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worrisome ailment in medicine: misleading journal articles; editors demand more data to ensure full disclosure of drug risks, trial gaps; Sarbanes-Oxley for professors.
    Mathews AW
    Wall St J (East Ed); 2005 May; ():A1, A9. PubMed ID: 15966125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.